Eli Lilly & Co stock kpis
Want to see LLY full AI Analyst Report?
Operating Expense Breakdown
Eli Lilly & Co reported operating expenses of $11.86B in Q3 2026, up 10.5% from Q2 2026 and up 64.1% year over year. This is the highest value since 2016.
Details spending on R&D, selling/general/admin and manufacturing to show how Lilly allocates cash between developing new drugs and running its commercial operations. Highlights whether the company is investing for long‑term growth, where cost pressure may hit margins, and how efficiently management turns spending into revenue.
Lilly is deliberately ratcheting up recurring R&D and marketing/S&A to fund massive new product launches, international rollouts and manufacturing scale, while large, episodic acquired IPR&D and impairment items from aggressive M&A create pronounced lumpiness. Management absorbed hefty IPR&D charges in Q2 yet still raised guidance thanks to strong top‑line leverage, so current spend is driving durable growth but also earnings volatility; watch future IPR&D/impairment timing and MS&A cadence to judge whether margin gains persist as launch noise, pricing pressure and H2 seasonality normalize.
LLY Operating Expense Breakdown
| Period | Research and Development | Marketing, Selling, and Administrative | Acquired In-Process Research and Development | Impairment, Restructuring, and Other | Total |
|---|---|---|---|---|---|
| Q3 2026Sep 30, 2026 | $4.25B | $3.13B | $4.18B | $303.00M | $11.86B |
| Q2 2026Jun 30, 2026 | $3.82B | $3.43B | $2.78B | $703.00M | $10.73B |
| Q1 2026Mar 31, 2026 | $3.51B | $2.93B | $584.00M | $279.00M | $7.31B |
| Q4 2025Dec 31, 2025 | $3.80B | $3.13B | $528.80M | $84.10M | $7.55B |
| Q3 2025Sep 30, 2025 | $3.47B | $2.74B | $655.70M | $364.90M | $7.23B |
| Q2 2025Jun 30, 2025 | $3.34B | $2.75B | $153.80M | $0.00 | $6.24B |
| Q1 2025Mar 31, 2025 | $2.73B | $2.47B | $1.57B | $35.00M | $6.81B |
| Q4 2024Dec 31, 2024 | $3.02B | $2.42B | $189.20M | $344.00M | $5.98B |
| Q3 2024Sep 30, 2024 | $2.73B | $2.10B | $2.83B | $81.60M | $7.74B |
| Q2 2024Jun 30, 2024 | $2.71B | $2.12B | $154.30M | $435.00M | $5.42B |
| Q1 2024Mar 31, 2024 | $2.52B | $1.95B | $110.50M | $0.00 | $4.59B |
| Q4 2023Dec 31, 2023 | $2.56B | $1.92B | $622.60M | $6.77M | $5.12B |
| Q3 2023Sep 30, 2023 | $2.41B | $1.80B | $2.98B | $0.00 | $7.19B |
| Q2 2023Jun 30, 2023 | $2.36B | $1.93B | $97.10M | $0.00 | $4.38B |
| Q1 2023Mar 31, 2023 | $1.99B | $1.75B | $105.00M | $0.00 | $3.84B |
| Q4 2022Dec 31, 2022 | $2.00B | $1.64B | $240.10M | $38.10M | $3.92B |
| Q3 2022Sep 30, 2022 | $1.80B | $1.61B | $62.40M | $206.50M | $3.69B |
| Q2 2022Jun 30, 2022 | $1.78B | $1.63B | $440.40M | $0.00 | $3.85B |
| Q1 2022Mar 31, 2022 | $1.61B | $1.56B | $165.60M | $0.00 | $3.33B |
| Q4 2021Dec 31, 2021 | $1.96B | $1.59B | $437.70M | $104.50M | $4.09B |
| Q3 2021Sep 30, 2021 | $1.71B | $1.58B | $177.60M | $0.00 | $3.46B |
| Q2 2021Jun 30, 2021 | $1.67B | $1.69B | $42.80M | $0.00 | $3.40B |
| Q1 2021Mar 31, 2021 | $1.68B | $1.58B | $312.00M | $211.60M | $3.78B |
| Q4 2020Dec 31, 2020 | $1.84B | $1.55B | $366.30M | -$30.10M | $3.73B |
| Q3 2020Sep 30, 2020 | $1.47B | $1.57B | $0.00 | $101.40M | $3.14B |
| Q2 2020Jun 30, 2020 | $1.39B | $1.45B | $241.80M | $0.00 | $3.08B |
| Q1 2020Mar 31, 2020 | $1.39B | $1.55B | $52.30M | $59.90M | $3.05B |
| Q4 2019Dec 31, 2019 | $1.58B | $1.70B | $0.00 | $151.70M | $3.43B |
| Q3 2019Sep 30, 2019 | $1.38B | $1.41B | $77.70M | $0.00 | $2.87B |
| Q2 2019Jun 30, 2019 | $1.40B | $1.59B | $25.00M | $0.00 | $3.01B |
| Q1 2019Mar 31, 2019 | $1.23B | $1.52B | $136.90M | $423.90M | $3.31B |
| Q4 2018Dec 31, 2018 | $1.45B | $1.86B | $329.40M | $246.00M | $3.89B |
| Q3 2018Sep 30, 2018 | $1.34B | $1.62B | $30.00M | $83.30M | $3.07B |
| Q2 2018Jun 30, 2018 | $1.33B | $1.65B | $1.62B | $74.40M | $4.69B |
| Q1 2018Mar 31, 2018 | $1.18B | $1.50B | $0.00 | $78.30M | $2.76B |
| Q4 2017Dec 31, 2017 | $1.47B | $1.78B | $50.00M | $1.00B | $4.31B |
| Q3 2017Sep 30, 2017 | $1.32B | $1.56B | $205.00M | $406.50M | $3.49B |
| Q2 2017Jun 30, 2017 | $1.25B | $1.71B | $0.00 | $50.00M | $3.01B |
| Q1 2017Mar 31, 2017 | $1.24B | $1.54B | $857.60M | $213.90M | $3.85B |
| Q4 2016Dec 31, 2016 | $1.45B | $1.79B | $30.00M | $147.60M | $3.42B |
| Q3 2016Sep 30, 2016 | $1.24B | $1.57B | $0.00 | $45.50M | $2.85B |
| Q2 2016Jun 30, 2016 | $1.34B | $1.62B | $0.00 | $58.00M | $3.02B |
| Q1 2016Mar 31, 2016 | $1.22B | $1.47B | $0.00 | $131.40M | $2.83B |

